Group 1: Market Performance - US stock market opened mixed with Dow Jones down 0.35%, Nasdaq up 0.02%, and S&P 500 down 0.08% [1] - Semiconductor sector weakened, with Intel dropping over 12% as the company projected first-quarter revenue guidance below market expectations of $12.51 billion [1] Group 2: Company-Specific News - Intel's stock plummeted 13% pre-market due to disappointing earnings guidance, with CEO Pat Gelsinger stating that the company's 18A process yield has not met expectations and that they are currently in a "just-in-time" production state, severely limiting supply capacity [3] - Moderna's stock fell over 3% as the company announced it would not invest in new late-stage vaccine trials [1] - Ericsson's stock rose 8% after the company reported fourth-quarter net sales and adjusted EBIT that exceeded expectations [1] Group 3: Financial Sector Developments - Bank of America and Citigroup are considering responding to President Trump's proposal for a 10% cap on credit card interest rates, with discussions ongoing about potential consumer cost reduction strategies [4] Group 4: Leadership Changes - Apple's CEO successor candidate, John Ternus, has had his responsibilities expanded, solidifying his position as a potential replacement for Tim Cook, as he now oversees the design team, a role historically held by senior leaders [5] Group 5: Short Selling and Stock Performance - Short sellers of SanDisk have incurred losses of approximately $3 billion since early November, as the stock has surged 112% year-to-date, leading to increased short squeeze risks [6] Group 6: IPO Highlights - Czechoslovak Group (CSG), a European ammunition manufacturer, saw its stock rise over 29% on its first day of trading in Amsterdam, raising €3.3 billion, marking the largest IPO in the history of pure defense companies [7]

Group 1 - Moderna's stock fell over 3% following the announcement that the company does not plan to invest in new late-stage vaccine trials [1]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced the appointment of Meng Jiange as a director of Legend Biotech Corporation, effective from January 20, 2026, replacing Zhu Li who will resign on the same date [1]. Group 1 - Kingsray Biotechnology is a company that has a joint venture with Legend Biotech Corporation, which is listed on the NASDAQ Global Select Market [1]. - The appointment of Meng Jiange is part of the governance changes within the board of Legend Biotech [1]. - Zhu Li will step down from the board on the effective date, indicating a transition in leadership [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇生物科技股份有限公司委任董事 本自願性公告由金斯瑞生物科技股份有限公司（「本公司」）作出。 本公司董事會（「董事會」）欣然宣佈，自2026年1月20日（「生效日期」）起，傳奇 生物科技股份有限公司（「傳奇」，為本公司聯營公司，其股份以美國存託股份形式 於美國納斯達克全球精選市場上市）董事會（「傳奇董事會」）任命孟建革先生 （「孟建革先生」）為董事，初始任期至傳奇2026年周年股東大會為止。孟建革先生 獲委任接替朱力博士於傳奇董事會的職務，朱力博士於生效日期辭任該職務。 2 孟建革先生於生命科學及生物科技領域擁有豐富的高級管理、財務及公司治理經驗。 其現任本公司主席及執行董事，自2010年起即於本公司擔任多個職務。加入本公司前， 孟建革先生曾於Quay Magnesium、 ...

Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for a Phase III clinical trial of its innovative polypeptide drug RAY1225 injection, targeting obesity combined with obstructive sleep apnea [1] Group 1 - RAY1225 injection is an innovative polypeptide drug developed by Zhongsheng Ruichuang, possessing global intellectual property rights [1] - The drug exhibits dual agonistic activity on GLP-1 and GIP receptors, indicating its potential effectiveness in treating obesity-related conditions [1] - RAY1225 injection is characterized by excellent pharmacokinetic properties, allowing for administration once every two weeks, showcasing its long-acting potential [1]

Group 1 - The core point of the article is that Zhifei Biological (300122) reported the number of common stock shareholders as of January 20, 2026, which stands at 121,021 households [1]

Group 1 - The core viewpoint of the article is that the stock price of Boya Bio (300294) in the secondary market is influenced by macroeconomic conditions, market policies, and investor risk preferences [1] Group 2 - The company advises investors to refer to its regular reports for information regarding its operational performance [1]

Group 1: Clinical Data and Impact - The combination therapy of mRNA-4157 and PD-1 inhibitor pembrolizumab significantly reduces the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients after complete resection, with stable efficacy observed over five years of follow-up [1] - This clinical data is seen as the first long-term survival benefit evidence for mRNA technology in non-infectious diseases, providing a boost to the global cancer immunotherapy field [1] Group 2: mRNA Technology Advantages - mRNA technology allows for the direct translation of specific antigen proteins in the body, inducing a specific immune response, and is considered a third-generation drug development platform [2] - The long-term market potential of mRNA technology is gradually becoming evident, with predictions estimating the global mRNA drug market to reach approximately $18 billion by 2024, potentially growing to over $43 billion in the next decade [2] Group 3: Domestic Companies' Initiatives - Domestic companies are actively laying out their strategies in the mRNA sector, with Ginkgo Bioworks' personalized mRNA cancer vaccine EVM16 having initiated its first human clinical trial in China [3] - Ginkgo Bioworks' vaccine is based on its proprietary AI algorithm system, which has shown the ability to identify both reported and novel tumor antigens [3] Group 4: Key Technological Developments - The nano-delivery system is identified as a critical technological bottleneck in mRNA drug development, significantly affecting drug efficacy and clinical translation [4] - Jitai Technology has developed a liver-targeted LNP delivery system for mRNA encoding bispecific antibodies, which has received orphan drug designation in the U.S. and is currently in clinical development [4] Group 5: Competitive Landscape - Jiachenshihai has multiple technology platforms, including mRNA and self-replicating RNA, and has developed a unique ready-to-use delivery carrier that enhances vaccine accessibility [5] - Other companies such as CSPC Pharmaceutical Group, CanSino Biologics, and Yuyuan Pharmaceutical have also reported their involvement in mRNA technology platforms [5]

Core Viewpoint - The company has proactively and prudently adjusted the pricing of its shingles vaccine to activate market potential and fulfill corporate social responsibility, aiming to alleviate the economic burden of vaccination, especially for the elderly population [1] Group 1 - The company is focused on expanding the coverage of its shingles vaccine among target populations, particularly the middle-aged and elderly [1] - The company is enhancing its market penetration by improving channel distribution and increasing terminal coverage [1] - The adjustments in pricing are intended to promote broader access to the vaccine while maintaining existing product coverage [1]

Group 1 - The core viewpoint of the article indicates that Kanghua Biological is forecasting a significant decline in its net profit for the fiscal year 2025, with an expected range of 191 million to 233 million yuan, representing a year-on-year decrease of 41.55% to 52.09% compared to the previous year's net profit of 399 million yuan [2] Group 2 - The company anticipates a challenging financial outlook for 2025, which may impact investor sentiment and market performance [2] - The projected decline in net profit highlights potential operational or market challenges that the company may be facing [2] - The announcement reflects broader trends in the industry that could affect similar companies and their financial forecasts [2]